Bio-Path Holdings, Inc. · OTC:BPTH

Bio-Path — Investor Presentation (March 2021)

17 slides from Bio-Path's investor presentation, March 2021

  1. Slide 1: Bio-Path Holdings: An Oncology-Focused Biotechnology Company

    Slide 1: Bio-Path Holdings: An Oncology-Focused Biotechnology Company

    Bio-Path Holdings An Oncology-Focused Biotechnology Company March 2021

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

  3. Slide 3: Introducing Bio-Path Holdings

    Slide 3: Introducing Bio-Path Holdings

    Introducing Bio-Path Holdings Advanced Oligonucleotide Therapeutics with High Efficiency Systemic Delivery Publicly traded Employees, Established NASDAQ Contractors & Houston, TX BPTH Consultants 2007 14 Technology Highlights ® DNAbilize Technology, next generation single-stranded DNA antisense Robu

  4. Slide 4: Robust Oncology Pipeline

    Slide 4: Robust Oncology Pipeline

    Robust Oncology Pipeline Preclinical IND PHASE 1 PHASE 2 Prexigebersen (BP1001, Liposomal Grb2) AML* *Orphan drug designation from the USFDA and Prexigebersen-A (BP1001-A) Solid Tumors (ovarian, endometrial, EMA for AML pancreatic) BP1002 (Liposomal Bcl-2) Lymphoma, CLL BP1002 (Liposomal Bcl-2) AML

  5. Slide 5: DNAbilize Technology

    Slide 5: DNAbilize Technology

    DNAbilize Technology ® Proven As Safe, Robust and Targeted Method for Treating Disease No Toxicity No Toxicity With human patients to date in prexigebersen clinical trial. • DNAbilize™ liposome structure is similar to the cellular membrane • P-ethoxy DNA does not induce hepatotoxicity or thrombocyto

  6. Slide 6: Prexigebersen Phase 1 Clinical Trial Conclusions

    Slide 6: Prexigebersen Phase 1 Clinical Trial Conclusions

    Prexigebersen Phase 1 Clinical Trial Conclusions Results support that Grb2 is a potential therapeutic target for haematological malignancies • Favorable safety profile strongly suggests that prexigebersen has a very different toxicity profile than other antisense oligonucleotide analogues, which hav

  7. Slide 7: Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy

    Slide 7: Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy

    Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy • Treatment of untreated AML patients who are induction therapy ineligible and unfit for stem cell transplant • Efficacy trial conducted at 6 leading cancer centers in the U.S., including the MD Anderson Cancer Ce

  8. Slide 8: Safety Segment Phase 2 Prexigebersen + LDAC Combination Therapy

    Slide 8: Safety Segment Phase 2 Prexigebersen + LDAC Combination Therapy

    Safety Segment Phase 2 Prexigebersen + LDAC Combination Therapy Showed Excellent Results Relapsed/refractory AML patients - 3 evaluable patients per cohort, 2 cohorts, n=6 - Dose 60 mg/m2 and 90 mg/m2 respectively - Received drug 2x week for 4 weeks per treatment cycle Results - 3 patients achieved

  9. Slide 9: Results of Stage 1 Interim Analysis

    Slide 9: Results of Stage 1 Interim Analysis

    Results of Stage 1 Interim Analysis Patient evaluation summary 5 Patients achieved CR (30%) Note: LDAC alone CR rate 7-13% 6 Patients achieved stable disease (35%) +65% 17 2 Stable disease patients had >50% bone marrow blasts reductions 1 CR patient was eligible for and received a bone marrow transp

  10. Slide 10: Prexigebersen-A Phase 1 Study in Solid Tumors

    Slide 10: Prexigebersen-A Phase 1 Study in Solid Tumors

    Prexigebersen-A Phase 1 Study in Solid Tumors • Prexigebersen-A is a modified product that incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties • Prexigebersen-A efficacy against ovarian tumors was enhanced when com

  11. Slide 11: BP1002 – A Phase 1 Study in Lymphoma and CLL

    Slide 11: BP1002 – A Phase 1 Study in Lymphoma and CLL

    BP1002 – A Phase 1 Study in Lymphoma and CLL • BP1002 is an RNAi antisense nanoparticle targeting Bcl-2 • BP1002 decreased viability of lymphoma cells (11 of 15 lymphoma cell lines) • By blocking Bcl-2 protein expression, BP1002 allows chemotherapy and radiation to activate apoptosis • BP1002 extend

  12. Slide 12: BP1003 Targeting STAT3

    Slide 12: BP1003 Targeting STAT3

    BP1003 Targeting STAT3 • BP1003 has efficacy against non-small cell lung cancer, AML, and pancreatic cancer cells • BP1003 + gemcitabine combination is efficacious in pancreatic cancer-derived tumors in animals • IND enabling studies during 2020 - 2021 • Goal is to submit a new IND in 2021 • Conduct

  13. Slide 13: Experienced Leadership Team

    Slide 13: Experienced Leadership Team

    Experienced Leadership Team Officer and Director Peter Nielsen since founding Michael Hickey 20+ years experience across all phases of drug Co-Founder, President, Company in 2007 Director Clinical development Chief Executive Officer Program Management and Chief Financial Manufacturing Officer Point

  14. Slide 14: Scientific Advisory Board

    Slide 14: Scientific Advisory Board

    Scientific Advisory Board Jorge Cortes, M.D. • Director, Cancer Center at Augusta University • Georgia Research Alliance Eminent Scholar in Cancer Chairman • Formerly, Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department

  15. Slide 15: IP and Financial Snapshot

    Slide 15: IP and Financial Snapshot

    IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patent issued covers DNAbilize ® technology, solely owned by Bio-Path • Four patents issued • Four additional patents pending Financial Snapshot • Ticker: NASDAQ: BPTH •

  16. Slide 16: Accomplishments in 2020

    Slide 16: Accomplishments in 2020

    Accomplishments in 2020 ➢ Successfully completed preclinical efficacy studies for the triple combination treatment of prexigebersen, decitabine and venetoclax in AML cell lines, suggesting significant enhancement in the efficacy of the frontline treatment. ➢ Presented a poster at the 2020 American A

  17. Slide 17: Thank you

    Slide 17: Thank you

    Bio-Path Holdings Thank you Bio-Path Holdings, Inc. 4710 Bellaire Blvd Suite 210 Bellaire, TX 77401 Web: www.biopathholdings.com Mail: partnering@biopathholdings.com Tel: (832) 742-1369 17

Source: Internet Archive copy of biopathholdings.com

More decks from Bio-Path Holdings, Inc.

All 11 Bio-Path decks